Market Overview

UPDATE: Piper Jaffray Reduces PT to $4.50 on Exelixis on Equity Financing Dilution

Share:
Related EXEL
Benzinga's Option Alert Recap From May 23
Mid-Afternoon Market Update: Dow Climbs 150 Points; Foot Locker Shares Drop On Earnings Miss

Piper Jaffray reiterated its Neutral rating on Exelixis (NASDAQ: EXEL) and reduced its price target from $5.50 to $4.50.

Piper Jaffray said, "Exelixis raised net proceeds of $120 million by issuing 30 million shares at $4.25 and $250 million from a 4.25% convertible note bringing proforma cash to $665 million. Cabozantinib has a November 29th PDUFA date in medullary thyroid cancer (MTC). Both the COMET-1 and COMET-2 pivotal studies are underway in castrate resistant prostate cancer (CRPC) plus 11 investigator sponsored trials (ISTs) under a CRADA funded by the NCI. … We are trimming our price target to $4.50 from $5.50 to account for dilution from the deals."

Exelixis closed at $4.38 on Friday.

Latest Ratings for EXEL

DateFirmActionFromTo
Mar 2017NeedhamInitiates Coverage OnBuy
Mar 2017OppenheimerInitiates Coverage OnPerform
Feb 2017Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for EXEL
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Intraday Update Analyst Ratings

 

Related Articles (EXEL)

View Comments and Join the Discussion!